# US 2009/0275541 A1 · Method for treating neurocognitive dysfunction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0275541 A1
- Document ID: US20090275541A1
- Status: Published application
- Kind: A1
- Application number: 12/151,200
- Filed: 2008-05-05
- Published: 2009-11-05
- Earliest claimed: 2008-05-05
- Assignees: Tonix Pharma Holdings Limited
- Inventors: Gregory M. Sullivan
- Web page: https://patentgrep.com/patent/US20090275541A1

## CPC

- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating corticosteroid-induced cognitive impairment comprises administering an effective amount of at least one compound of formula I, or pharmaceutically acceptable salts thereof, to a subject in need of such treatment. Formula I is: wherein: A is a bridge selected from the following radicals: —(CH2)m—, —CH═CH—, —(CH2)p—O—, —(CH2)p—S—, —(CH2)p—SO2—, —(CH2)p—NR1— and —SO2—NR2—, and wherein: m is an integer of from 1 to 3 inclusive; p is an integer selected from 1 and 2; R1 is selected from the group consisting of hydrogen and C1-C5 alkyl; and R2 is C1-C5 alkyl; X and Y are independently selected from the group consisting of hydrogen and halogen; R and R′ are independently selected from the group consisting of hydrogen and C1-C5 alkyl; n is an integer from 1 to 12 inclusive; and * denotes an asymmetric carbon.

## Claims

### Claim 1

A method of treating the neurocognitive side effects associated with corticosteroid treatment as a result of a condition in a subject in need of such treatment, comprising administering to the subject an effective amount of at least one compound of formula I
wherein: A is a bridge selected from the following radicals: —(CH2)m—, —CH═CH—, —(CH2)p—O—, —(CH2)p—S—, —(CH2)p—SO2—, —(CH2)p—NR1— and —SO2—NR2—, and wherein: m is an integer of from 1 to 3 inclusive; p is an integer selected from 1 and 2; R1 is selected from the group consisting of hydrogen and C1-C5 alkyl; and R2 is C1-C5 alkyl; X and Y are independently selected from the group consisting of hydrogen and halogen; R and R′ are independently selected from the group consisting of hydrogen and C1-C5 alkyl; n is an integer from 1 to 12 inclusive; and * denotes an asymmetric carbon and the bond designated by {character pullout} indicates that the absolute conformation about the asymmetric carbon can be either (R) or (S) only when all four groups attached to the asymmetric carbon are nonequivalent, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein A is —SO2—NR2—.

### Claim 3 (depends on 2)

The method according to claim 2, wherein R and R′ are hydrogen.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound of formula I is tianeptine or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the compound is (R)-tianeptine, substantially free of the corresponding (S)-enantiomer.

### Claim 6 (depends on 4)

The method of claim 4, wherein the compound is (S)-tianeptine, substantially free of the corresponding (R)-enantiomer.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 8 (depends on 1)

The method of claim 1, wherein the effective amount of the at least one compound of formula I administered to the subject is from about 2 to about 600 mg/day.

### Claim 9 (depends on 1)

The method of claim 1, wherein the effective amount of the at least one compound of formula I administered to the subject is from about 10 to about 400 mg/day.

### Claim 10 (depends on 1)

The method of claim 1, wherein the effective amount of the at least one compound of formula I administered to the subject is about 25 to about 300 mg/day.

### Claim 11 (depends on 1)

The method of claim 1, wherein the at least one compound of formula I is administered to the subject as a pharmaceutical composition.

### Claim 12 (depends on 11)

The method of claim 11, wherein the condition is pulmonary condition.

### Claim 13 (depends on 12)

The method of claim 12, wherein the pulmonary condition is selected from the group consisting of asthma, chronic obstructive pulmonary disease and pulmonary sarcoidosis.

### Claim 14 (depends on 11)

The method of claim 11, wherein the condition is selected from the group consisting of a cardiac condition, a gastrointestinal condition, a rheumatic condition, a collagen-vascular or dermatological condition, a renal condition, an endocrine condition.

### Claim 15 (depends on 14)

The method of claim 14, wherein the condition is pericarditis, hepatitis, ulcerative colitis or Crohn's disease, rheumatoid arthritis or psoriatic arthritis, polymyositis, polyarteritis nodosa, vasculitis, systemic dermatomyositis, eczema, cutaneous sarcoidosis, mycosis fungoides, severe seborrheic dermatitis, psoriasis, and systemic lupus erythematosus, nephritic syndrome, or lupus nephritis, a hyperthyroid state or hypercalcemia associated with malignancy and sarcoidosis.

### Claim 16 (depends on 11)

The method of claim 11, wherein the condition is the prophylaxis of the rejection of a transplanted organ.

### Claim 17 (depends on 1)

The method of claim 1, wherein the compound of formula I is administered with a systemic corticosteroid.

### Claim 18 (depends on 17)

The method of claim 17, wherein the systemic corticosteroid is prednisone.

### Claim 19

A pharmaceutical composition comprising a systemic corticosteroid and a compound of formula I.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the compound is tianeptine.

### Claim 21 (depends on 19)

The pharmaceutical composition of claim 19, wherein the compound is (R)-tianeptine, substantially free of the corresponding (S)-enantiomer.

### Claim 22 (depends on 19)

The pharmaceutical composition of claim 19, wherein the compound is (S) tianeptine, substantially free of the corresponding (R)-enantiomer.

### Claim 23 (depends on 19)

The pharmaceutical composition of claim 19, wherein the systemic corticosteroid is prednisone.
